OPEXA THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. OPEXA THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 2.62 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 29.25% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY15||Q4 FY14|
|Net Sales ($mil)||0.73||0.31|
|Net Income ($mil)||-2.38||-3.36|
|Balance Sheet||Q4 FY15||Q4 FY14|
|Cash & Equiv. ($mil)||12.58||9.91|
|Total Assets ($mil)||14.42||11.8|
|Total Debt ($mil)||0.15||0.0|
|Profitability||Q4 FY15||Q4 FY14|
|Gross Profit Margin||100.0||100.0|
|Return on Assets||-83.36||-127.53|
|Return on Equity||-125.0||-202.33|
|Debt||Q4 FY15||Q4 FY14|
|Share Data||Q4 FY15||Q4 FY14|
|Shares outstanding (mil)||6.98||3.53|
|Div / share||0.0||0.0|
|Book value / share||1.38||2.11|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||38761.0||251198.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 1.71 indicates a discount versus the S&P 500 average of 2.74 and a significant discount versus the industry average of 10.13. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, OPEXA THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|OPXA NM||Peers 184.93||OPXA NM||Peers 37.67|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
OPXA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
OPXA's P/CF is negative making the measure meaningless.
|OPXA NM||Peers 30.59||OPXA NA||Peers 1.51|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
OPXA's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|OPXA 1.71||Peers 10.13||OPXA 47.23||Peers 23.46|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
OPXA is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
OPXA is expected to have an earnings growth rate that significantly exceeds its peers.
|OPXA 6.41||Peers 293.90||OPXA 100.94||Peers 47.38|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
OPXA is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
OPXA has a sales growth rate that significantly exceeds its peers.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.